Citadel Advisors’s NxStage Medical Inc. NXTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-29,600
| Closed | -$826K | – | 10178 |
|
|
2018
Q3 | $826K | Sell |
29,600
-6,000
| -17% | -$169K | ﹤0.01% | 5869 |
|
|
2018
Q2 | $993K | Buy |
35,600
+4,700
| +15% | +$126K | ﹤0.01% | 5226 |
|
|
2018
Q1 | $768K | Buy |
30,900
+8,500
| +38% | +$207K | ﹤0.01% | 5208 |
|
|
2017
Q4 | $543K | Buy |
22,400
+4,000
| +22% | +$105K | ﹤0.01% | 5526 |
|
|
2017
Q3 | $508K | Buy |
+18,400
| New | +$491K | ﹤0.01% | 5297 |
|
|
2016
Q2 | – | Sell |
-10,900
| Closed | -$163K | – | 7731 |
|
|
2016
Q1 | $163K | Buy |
10,900
+5,100
| +88% | +$85.5K | ﹤0.01% | 5776 |
|
|
2015
Q4 | $127K | Sell |
5,800
-4,700
| -45% | -$87.6K | ﹤0.01% | 6421 |
|
|
2015
Q3 | $166K | Buy |
10,500
+4,400
| +72% | +$70.5K | ﹤0.01% | 6382 |
|
|
2015
Q2 | $87K | Buy |
+6,100
| New | +$103K | ﹤0.01% | 7225 |
|
|
2015
Q1 | – | Sell |
-1,200
| Closed | -$22K | – | 9017 |
|
|
2014
Q4 | $22K | Sell |
1,200
-7,400
| -86% | -$119K | ﹤0.01% | 7746 |
|
|
2014
Q3 | $113K | Buy |
8,600
+8,100
| +1,620% | +$109K | ﹤0.01% | 6299 |
|
|
2014
Q2 | $7K | Sell |
500
-2,400
| -83% | -$31.3K | ﹤0.01% | 7680 |
|
|
2014
Q1 | $37K | Buy |
2,900
+1,300
| +81% | +$17K | ﹤0.01% | 6968 |
|
|
2013
Q4 | $16K | Sell |
1,600
-1,300
| -45% | -$14.8K | ﹤0.01% | 6581 |
|
|
2013
Q3 | $38K | Sell |
2,900
-1,000
| -26% | -$13.1K | ﹤0.01% | 5936 |
|
|
2013
Q2 | $56K | Buy |
+3,900
| New | +$49K | ﹤0.01% | 5607 |
|
Other funds holding NXTM
Citadel Advisors's NXTM Position: Q1 2019 in Review
Citadel Advisors sold out of NxStage Medical Inc. (NXTM) in Q1 2019, closing a stake of 1,662,607 shares — an estimated $47.6M sold.
Citadel Advisors first reported a position in NXTM in Q2 2013 and held it in 20 quarters. The position peaked at $47.6M in Q4 2018. 1 fund tracked by Wall St. Rank holds NXTM as of Q1 2019.
- Citadel Advisors reported no remaining NxStage Medical Inc. position as of Q1 2019 after selling out during the quarter.
- Citadel Advisors sold 1,662,607 NxStage Medical Inc. shares in Q1 2019, an estimated $47.6M.
- Citadel Advisors first reported a position in NxStage Medical Inc. in Q2 2013 and held it in 20 quarters.
- Citadel Advisors's NxStage Medical Inc. position peaked at $47.6M in Q4 2018.
- 1 fund tracked by Wall St. Rank held NxStage Medical Inc. as of Q1 2019.
Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.